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Abstract
Nitric oxide synthase (NOS), a flavo‐hemoprotein, regulates nitric oxide (NO) synthesis 
that has dual biological activities: as an important signalling molecule in vasodilatation 
and neurotransmission at low concentrations and at higher concentrations as a defensive 
cytotoxin. In central and peripheral nervous system, neuronal NOS (nNOS) produces 
NO that has been implicated in modulating physiological functions such as synaptic 
plasticity, learning, memory and neurogenesis as well as some pathological conditions 
in which overproduction of NO may lead to the generation of highly reactive species, 
such as peroxynitrite and stable nitrosothiols, which may cause irreversible cell damage 
in excitotoxicity, ischaemia, Parkinson, Alzheimer's disease (AD) and depression. NOS‐
derived NO also involves in regulation of blood pressure, smooth muscle relaxation and 
gut peristalsis via peripheral nitrergic nerves.
Keywords: neuronal nitric oxide synthase, nitric oxide
1. Introduction
After discovery of nitric oxide as a biological mediator many researchers have focused on the 
importance of nitric oxide in the physiology of the nervous system [1–3].
NO, as the smallest signalling molecule, is produced by three types of NO synthase arising 
from three different genes referred to as neuronal nitric oxide synthase (also known as nNOS, 
Type I, NOS‐I and NOS‐1) that is found in neuronal tissues, inducible nitric oxide synthase 
(also known as iNOS, Type II, NOS‐II and NOS‐2) that is synthesized after formation of pro‐
inflammatory cytokines or endotoxin and endothelial nitric oxide synthase (also known as 
eNOS, Type III, NOS‐III and NOS‐3) that is found in endothelial cells [4]. The nNOS and 
eNOS are constitutively expressed and considered to be calcium‐dependent, but when the 
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activity of iNOS is fully activated at basal intracellular calcium concentration, it would be 
calcium‐independent.
The main difference between three NOS isoform regarding the reactions achieved lies in the 
rate of the nicotinamide‐adenine‐dinucleotide phosphate (NADPH) oxidation, termed the 
uncoupled reaction. Moreover, nNOS carry on transferring electrons to the haem and, hence, 
oxidase NADPH at a high rate, while in eNOS and iNOS this reaction can happen at a much 
slower rate [5].
The nNOS constitutes the principal source of NO in distinct populations of neurons and syn‐
aptic spines in the brain and the peripheral nervous system while eNOS can occur in some 
neurons and iNOS may exist in microglia and astrocytes but usually not in neurons [6].
Interneurons expressing nNOS are involved in physiological procedures like neurovascular 
coupling to regulate neocortical blood flow [7], the homeostatic control of sleep [8], synaptic 
integration of adult neurons and balance of excitatory and inhibitory signalling in brain [9].
2. nNOS enzymology
The nNOS monomer with a molecular weight of 160.8 kDa and 1434 amino acids is inactive 
and can be activated after dimerization by tetrahydrobiopterin (BH
4
), haem and l‐arginine 
(L‐Arg) binding [10]. Each nNOS monomer has two domains including a reductase domain 
(C‐terminal) and an oxygenase domain (N‐terminal) which can be separated by a calmod‐
ulin‐binding motif [11]. The reductase domain which attaches the substrate NADPH com‐
prises a binding site for flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) 
[12, 13]. An autoinhibitory loop within the FMN‐binding domain regulates nNOS activity 
[10]. The oxygenase domain which binds the substrate l‐arginine contains BH
4
 binding site, 
cytochrome P‐450‐type haem active site and Zn binding site for nNOS dimerization facilita‐
tion (Figure 1).
Figure 1. Schematic demonstration of nNOS structure and the metabolic formation of nitric oxide by nNOS include an 
oxygenase domain (N‐terminal) and a reductase domain (C‐terminal) which can be separated by a calmodulin‐binding 
motif. The reductase domain which binds NADPH includes a binding site for FMN, FAD and the oxygenase domain 
which binds l‐arginine contains a tetrahydrobiopterin (BH
4
) binding site and a cytochrome P‐450‐type haem active site. 
NADPH electrons (e‐) via FMN and FAD transfer from the reductase domain to the oxygenase domain. nNOS catalyzes 
the oxidation of l‐arginine to form l‐citrulline and NO (Reproduced with permission from Dong‐Ya Zhu).
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All NOS proteins comprise a zinc–thiolate cluster formed by a zinc ion that is tetrahedrally 
coordinated to two Cys motifs (one donated by each monomer) at the NOS dimer interface. 
Zinc in NOS has a catalytic activity [10].
3. NOS‐catalyzed reaction
All forms of NOS use l‐arginine and molecular oxygen as the substrate and reduced nicotin‐
amide‐adenine‐dinucleotide phosphate (NADPH) as co‐substrates to produce citrulline NO. 
FAD and FMN with BH
4
 are cofactors of all isozymes. All NOS proteins are homodimers. A 
functional NOS transfers electrons from NADPH, via FAD and FMN in the carboxy‐terminal 
reductase domain to the haem in the amino‐terminal oxygenase domain. This flowing of elec‐
tron (NADPH → FAD → FMN → haem) can be facilitated by Ca2+/CaM binding. The oxygen‐
ase domain also binds the cofactor BH
4
, molecular oxygen and l‐arginine. At the haem site, the 
electrons are used to activate O2 to oxidize l‐arginine to l‐citrulline and NO. Sequences near the cysteine ligand of the haem are also implicated in l‐arginine and BH
4
 binding. The NOS enzyme 
is monooxygenases, generating NO and citrulline from L‐arginine (L‐Arg), NADPH and O2.
The NOS catalysis has two‐step as follows: In first step, the substrate, L‐Arg, is con‐
verted to N‐hydroxy‐L‐arginine (NOHA), that in turn is converted to NO and citrulline 
in the second step. The nitrogen atom of NO is derived from the guanidino group of 
the l‐Arg substrate, and the oxygen atom is derived from dioxygen [10, 14]. NO can acti‐
vate some transduction pathways, such as, activation of guanylyl cyclase and conversion 
of Guanosine‐5’‐triphosphate (GTP) into Cyclic guanosine monophosphate (cGMP) and 
Figure 2. Signal transduction of nNOS. nNOS is activated by a calcium‐dependent calmodulin. nNOS produces NO 
from oxidation of arginine into citrulline. NO diffuses and act on pre‐synaptic or post‐synaptic targets. NO activates 
guanylyl cyclase (GC) that triggers a protein kinase G (PKG) resulting in Erk activation and the stabilization of TORC1 
a CREB co‐activator. PL. M, plasma membrane; CAT, cation and anion transporter. (Adapted from Gallo and Iadecola).
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consequent activation of protein kinase G (PKG). PKG activity leads to Erk activation of 
early genes such as c‐fos, Arc and Brain‐derived neurotrophic factor (BDNF) (Figure 2). 
NO/cGMP pathway is implicated in various neurophysiological processes including neu‐
ronal synaptic modulation, development, learning and memory. Some effects of NO are 
cGMP‐independent. For instance, several pre‐synaptic targets such as SNAP25, synthaxin 
Ia, n‐Sec 1, neurogranin as well as the post‐synaptic targets ADP ribosyltransferase and 
NMDA receptors have been identified for NO [15].
4. Histological distribution
The nNOS has been found in neurons, astrocytes, the adventitia of brain blood vessels and 
cardiac myocytes. Besides brain tissue, nNOS has been distinguished by immunohisto‐
chemistry in the spinal cord, sympathetic ganglia and adrenal glands, peripheral nitrergic 
nerves, skeletal and cardiac myocytes, epithelial cells of different organs, kidney macula 
densa cells, pancreatic islet cells, parasympathetic ganglia, nonadrenergic noncholinergic 
peripheral autonomic nerve fibres and the vascular smooth muscle and endothelial cells 
[16]. In mammalians, the largest origin of nNOS regarding tissue mass is the skeletal mus‐
cle [4, 16, 17].
Since NO cannot be stored in the cells, new synthesis is necessary to have its activities. Thus 
nNOS should be bonded to the plasma membrane directly or through adapter proteins. 
Fractionation studies have shown that brain nNOS occurs in particulate and soluble forms 
in cytosol far from membranes in a patch‐like form. Furthermore, through the early six days 
in the cultured cerebral cortical astrocytes of rats, nNOS immunoreactivity mostly appeared 
in the cytoplasm. Nevertheless, at day 7, nNOS immunoreactivity was predominantly 
expressed in the nucleus, and this nuclear localization continued about 10 h. Then, nNOS 
immunoreactivity was mainly expressed in the cytoplasm again. Recently, some researchers 
showed nNOS nuclear localization without cytoplasmic staining of nNOS in some parts of 
neural and glial cells. Therefore, diverse functions of nNOS in the cell may arise from dif‐
ferential subcellular localization [10].
Adapter proteins are involved in transfer of nNOS to distinct sites. For instance, nNOS 
is anchored to membranes by binding to syntrophin, PSD95/SAP90 or PSD93. CAPON, 
another adapter protein for nNOS, comprises a C‐terminal domain that binds to the PDZ 
domain of nNOS.
In rats and mice, five interneuron expressing nNOS have been found as follows: (1) neuro‐
gliaform cells, (2) Ivy cells (IvC), (3) interneurons expressing the vasoactive intestinal peptide 
(VIP) and calretinin (CR), (4) interneurons expressing PV and (5) projection cells close to the 
subiculum. PV cells expressing nNOS mainly exist in the dentate gyrus (DG) of hippocam‐
pus. Though species differences between rat and mouse have been noted that coexpression of 
nNOS and PV in rat DG is much lower than that in mouse. Somatostatin‐expressing interneu‐
rons that express nNOS are resided in hippocampus.
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5. Cofactors and prosthetic groups that impact on nNOS activity
5.1. Phosphorylation
Kinases increase nNOS activity by phosphorylation, whereas, phosphatases decrease nNOS 
activity by dephosphorylation [18]. nNOS phosphorylation is important for the enzyme activ‐
ity that is regulated by some kinases and phosphatases, for example, calmodulin‐dependent 
kinases, protein kinase C (PKC), protein kinase A (PKA) and phosphatase 1, which are in fact 
modulated by extracellular and intracellular factors [19]. Nonetheless, phosphorylation at 
different sites of nNOS affects its activity differently. The protein kinase CaMKII can phos‐
phorylate nNOS at Ser847 that diminishes nNOS activity by Ca2+–CaM binding inhibition. 
Ser847‐PO
4
 is found in the autoinhibitory loop which inhibits the movement of the loop even 
in the occurrence of high concentrations of Ca2+–CaM, thus decreasing nNOS activity [20]. 
In contrast, the protein phosphatase 1 decreases phosphorylation level of nNOS at Ser847, 
leading to an increased nNOS activity. Another phosphorylation site of nNOS is at Ser1412 
in endothelial nitric oxide synthase [21]. In addition, CaM‐KI deregulates nNOS activity by 
phosphorylation at Ser741 in transfected cells. Since the expression of CaM‐KI declines with 
the brain development, it still needs to be demonstrated whether nNOS is phosphorylated at 
Ser741 by CaM‐KI in vivo [10].
5.2. Dimerization
Despite the ability of the reductase and oxygenase domains that function independently in 
some circumstances, NOS activity is accomplished by the homodimer [5].
Active nNOS is a dimer with two high‐affinity binding sites for BH
4
 and l‐arginine. Two 
cysteine residues make a disulphide bridge or ligate a zinc ion to connect the two monomers. 
Furthermore, an ‘N‐terminal hook’ domain sustains the dimer. BH
4
 as well as haem and 
l‐arginine make nNOS a stable dimer.
High‐affinity binding sites for BH
4
 and l‐arginine and facilitating electron flow that occurs 
in dimerization raise nNOS activity. The electron seems to transfer from one monomer to 
another, which may be the main reason why the nNOS monomer is inactive. PIN (inhibitor 
of nNOS) destabilizes the nNOS dimer, thus inhibiting nNOS activity. Dimer stabilization 
preserves nNOS from proteolysis. Destabilization of dimeric nNOS makes it more vulnerable 
to be phosphorylated by protein kinase C and hydrolyzed by trypsin [5, 10]. nNOS monomers 
are able to catalyze the cytochrome c reduction. This shows that the electrons transfer within 
the reductase domain from NADPH by two flavins is independent of dimeric structure [5].
The haem plays a crucial role in dimerization. In absence of haem, NOS is monomer which is 
principally normal with respect to secondary structure [5].
5.3. Calcium and calmodulin
Dependence on Ca2+ is the main characteristic between the constitutive and inducible iso‐
forms. eNOS and nNOS are both triggered by an elevation in intracellular Ca2+, followed by 
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the consequent binding of Ca2+/CaM [5]. Calmodulin acts as an allosteric activator of all forms 
of NOS that facilitates electron flow transferring from NADPH to the reductase domain fla‐
vins and from the reductase domain to the haem center. Calmodulin binding is brought about 
by an increase in intracellular Ca2+ [22, 23].
When intracellular Ca2+ concentrations decline to basal levels, calmodulin detaches from 
nNOS, and it becomes inactive again. Hence, nNOS activity is primarily controlled by intra‐
cellular Ca2+ concentrations and so calmodulin‐binding effect on nNOS activity.
5.4. Proteins binding to nNOS PDZ domain
PDZ (Post Synaptic Density proteins, discs‐large, ZO‐1) domain of the NH2 terminal involves in dimerization, activation and interaction of nNOS with many other proteins in specific areas 
of the cell [24]. These interactions determine the sub‐cellular distribution and the function of 
the enzyme [4, 10].
nNOS PDZ domain contains two separate binding sites, one site binds to PDZ domains of 
other proteins and another site binds to COOH‐terminal peptide ligands. Proteins contain‐
ing PDZ domains are important in connecting constituents of signal transduction pathways 
in multiple complexes [25]. NO signalling is modified by nNOS attachment to membrane 
or cytosolic protein by direct PDZ–PDZ domain or C‐terminal‐PDZ interactions. PSD95 
(post‐synaptic density protein‐95), a multivalent synaptic protein and main component of 
the post‐synaptic density, can connect nNOS to N‐methyl‐d‐aspartate receptor (NMDAR), 
and elucidate the NMDAR stimulation effect on nNOS activation. Post‐synaptic targeting of 
nNOS is directed by binding to PSD95 (Figure 3). nNOS–PSD95 is a typical PDZ–PDZ bind‐
ing, which needs the intact tertiary structure of both domains and a 30‐amino acid extension.
CAPON, another adapter protein, comprises a C‐terminal PDZ domain that binds to the N‐
terminal of nNOS PDZ domain and an N‐terminal phosphotyrosine binding (PTB) domain. 
CAPON interacts with a component of the Ras family of small G proteins, Dexras1, which 
is induced by dexamethasone. Interaction of CAPON with nNOS delivers NO to Dexras1, 
leading to S‐nitrosylation of Dexras1 on cysteine‐11. Dexras1 binds to the peripheral benzodi‐
azepine receptor‐associated protein (PAP7), and PAP7 binds to the divalent metal transporter 
(DMT1), an iron channel mediating iron uptake in neurons [26]. Abnormally high cellular 
iron levels may lead to disordered neuronal function [27].
5.5. nNOS inhibitors
It has been shown that the N‐terminus of nNOS could bind to a protein termed PIN which 
can inhibit nNOS activity. It is found that PIN destabilizes nNOS dimers and inhibits nNOS 
activity. Recently, it has been demonstrated that PIN inhibits production of NO and O2, not nNOS dimerization [28].
Another protein that inhibits NO productions is nitric oxide synthase interacting protein 
(NOSIP) [29]. NOSIP and nNOS co‐localize in different areas of the central and peripheral 
nervous systems. NOSIP negatively affects nNOS activity in a neuroepithelioma cell line 
stably expressing nNOS. In addition, over‐expression of NOSIP in cultured primary neurons 
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limits nNOS trafficking to terminal dendrites and direct nNOS to the soma. These findings 
suggest that NOSIP regulates NO production in the nervous system by regulating the activ‐
ity and localization of nNOS. NOSIP upregulation by neuronal activity may prevent NO 
production in neurons [10].
6. Physiological and pathophysiological functions of nNOS
6.1. Physiological functions of nNOS
Even though nNOS‐derived NO has many functions in neuronal signalling, it varies from 
a physiological neuromodulator to a neurotoxic factor when extra amount of NO is gen‐
erated. Thus nNOS may play an important role in many physiological and pathologi‐
cal conditions [10]. Neuronal functions of nNOS are modulating physiological functions 
such as learning, memory and neurogenesis. In the central nervous system (CNS), nNOS‐
derived NO causes long‐term regulation of synaptic transmission (long‐term potentiation 
and long‐term inhibition) [30], while in acute neurotransmission there is no involvement. 
NOS inhibitors diminish learning and produce amnesia in animal models, so it involves in 
memory formation. Also in the CNS, nNOS‐derived NO is implicated in the central regula‐
tion of blood pressure. Blockade of nNOS activity in the medulla and hypothalamus makes 
systemic hypertension [31].
The nNOS‐derived NO as an important neurotransmitter is participated in neuronal plastic‐
ity (especially in memory formation), peripheral and central transmission of pain signals, 
Figure 3. PSD95–nNOS uncoupling agents dissociates the PSD95–nNOS interaction. Glutamate produces NMDAR 
activation, result in NMDAR/PSD95/nNOS complex formation, and thereby recruiting nNOS to the calcium pore of the 
NMDA receptor, which makes a principal component of excitotoxicity. PSD95–nNOS uncoupling agents may dissociate 
the PSD95–nNOS complex, thus, having a neuroprotective effect. More, particulary, PSD95–nNOS as uncoupling agent 
does not influence other pathway of PSD95 or nNOS, such as PSD95–GKAP, PSD95–SynGAP, nNOS–CAPON and 
nNOS–PFK‐M, therefore, physiological functions of nNOS, for example, learning, memory and neurogenesis, were not 
affected (Reproduced with permission from Dong‐Ya Zhu).
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 regulation of central nervous system blood flow, neurotransmitter release from cholinergic 
nerve fibres and the functional regulation of organs with nitrergic innervation [32].
6.1.1. Pancreatic nNOS and insulin regulation
Pancreatic β‐cells express nNOS that controls insulin secretion through two catalytic activi‐
ties: nitric oxide production and cytochrome c reductase activity [33].
PIN is primarily incorporated with insulin secretory granules and co‐located with nNOS. In 
addition, PIN overproduction increases glucose‐induced insulin secretion, which is reversed 
by NO donor, sodium nitroprusside. In contrast, nNOS inhibitor increased insulin secretion 
induced by glucose. Therefore, PIN insulinotropic effect could be related to its co‐localization 
with the actin‐based molecular motor myosin and as such be involved in the physiological 
regulation of insulin secretion at the exocytotic machinery [33].
6.1.2. Cardiovascular regulation
Sarcoplasmic reticulum and mitochondria functions are regulated by nNOS through Ca2+ 
maintaining, which are directly related to myocardial injury. nNOS overexpression protects 
mouse hearts from injury and nNOS deficiency increases ventricular arrhythmia and mortal‐
ity after myocardial infarction [34].
It is accepted that the local regulation of vascular tone in health is mainly regulated by eNOS‐
derived NO [35]. However, some studies have suggested that nNOS‐derived NO may also be 
implicated in this process and plays an important role in the local regulation of basal micro‐
vascular tone as well as in the vasodilator response to mental stress [35]. nNOS can regu‐
late vascular tone, independent of its effects in the central nervous system [35] and by direct 
effects on vascular smooth muscle. In the kidney S‐methyl‐l‐thiocitrulline (SMTC) as a selec‐
tive nNOS‐inhibitor can decrease basal afferent and efferent arteriolar tone. These studies 
showed that macula densa (the main source of renal nNOS) removal eliminate the vasocon‐
strictor effects of SMTC.
In cerebral vessels, nNOS may regulate vascular tone reflex especially in response to hypoxia 
and/or hypotension. For example, Bauser‐Heaton et al. have shown that selective inhibition of 
nNOS with N‐(4S)‐(4‐amino‐5‐[aminoethyl]aminopentyl)‐N'‐nitroguanidine decreased basal 
cerebral arterial diameter and eliminated the vasodilator response to hypoxia.
In skeletal muscle nNOS is located at the cell membrane bound to the cytoskeletal protein 
dystrophin. Dystrophin absence in patients with Duchenne muscular dystrophy (DMD) 
makes a significant reduction in skeletal muscle nNOS expression and also in blood flow.
In coronary microvascular system, nNOS and eNOS have distinct local roles in the physi‐
ologic regulation. While nNOS may be principal factor in regulation of basal vasomotor tone 
and blood flow, eNOS‐derived NO facilitates dynamic alterations in blood‐flow distribution 
and has anti‐atherosclerotic effects at endothelium.
Many smooth muscle tissues in the periphery are innervated by nitrergic nerves, that is, 
nerves that include nNOS that produce and release NO [4]. For example, relaxation of 
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 corpus cavernosum and penile erection is occurred by nitrergic nerves. Phosphodiesterase‐5 
inhibitors (sildenafil, vardenafil and tadalafil) need at least a residual nNOS activity for their 
action [4].
Some studies indicated that nNOS‐derived NO may change vascular tone by perivascular 
sympathetic nerve inhibition. Hatanaka et al. indicated that selective nNOS inhibitor, vinyl‐
l‐5‐(1‐imino‐3‐butenyl)‐l‐ornithine (l‐VNIO) raises arterial vasoconstriction and local norepi‐
nephrine concentration in perivascular nerve stimulation in isolated rat mesenteric arteries 
without endothelium. However, l‐VNIO could not alter vasoconstrictor response to exoge‐
nous norepinephrine, showing that nNOS‐derived NO may affect release of neurotransmitter 
from perivascular sympathetic nerves.
In other studies nNOS‐derived NO in central systems may change peripheral vascular tone. 
For instance, nitric oxidergic neurons in nucleus tractus solitaries influence on blood pressure 
in diabetic rats. Unilateral microinjection of sodium nitroprusside (100 mmol/60 nL) into the 
nucleus raised blood pressure in diabetic rats [36, 37]. In another study, it is revealed that 
nitric oxide in the nucleus raphe magnus modulates cutaneous blood flow in rats during 
hypothermia [38, 39].
6.1.3. Neurogenesis
NO as a paracrine messenger in newly produced neurons regulates the proliferation and dif‐
ferentiation of mouse brain neural progenitor cells. L‐NAME, NO synthase inhibitor, raises 
cell proliferation and reduces neuronal differentiation [40].
The subventricular zone (SVZ) and the subgranular zone (SGZ) of dentate gyrus are two prin‐
cipal neurogenesis sites in the adult brain. In the adult mouse SVZ and olfactory bulb, NO has 
a negative control on the size of the undifferentiated precursor pool and enhances neuronal 
differentiation so acts as a physiological inhibitor of neurogenesis [41].
Mice treated with 7‐NI display a rise in the number of mitotic cells in the SVZ, the olfactory 
bulb and the rostral migratory stream, but not in the DG. Though, a recent research estab‐
lished that nNOS inhibition elevated progenitor cells proliferation in the DG. Also, the anti‐
proliferative role of nNOS‐derived NO on SVZ and DG has been shown in cerebral ischaemia. 
Thus, endogenous NO‐derived nNOS can inhibit SVZ neurogenesis. Nevertheless, the role of 
nNOS in hippocampal neurogenesis is arguable. While nNOS‐derived NO has anti‐prolifera‐
tive effect in adult animals, NO donor administration induces neurogenesis. It may be due 
to the different experimental protocols. Intravenous or hippocampal administration of a NO 
donor which can result in raised NO levels enhances cerebral blood flow, indirectly influenc‐
ing neurogenesis [10].
6.1.4. Cerebral maps formation
NO has been involved in the cerebral map formation. In visual system, NO prompts synap‐
tic refinement of immature synaptic connections at retinothalamic and retinocollicular levels. 
Normal organization of the somatosensory cortex and barrel field plasticity were found by daily 
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injection of nitroarginine before the period of ocular dominance column formation. However, 
NO may still contribute in establishing and refining neocortical connectivity. Definitely, when 
NADPHd activity is reformed in the barrel field, abnormal separation of thalamocortical axons 
happens. In these animals thalamocortical axons show fewer branch points in layer IV and 
abnormally expansive thalamocortical arbors. These results propose that NO could promote 
thalamocortical sprouting and participates in the consolidation of synaptic strength in layer IV 
of the primary somatosensory cortex [40].
6.1.5. Synchronization and coordination
Also, regulation of gap junctions is mediated by NO. Rorig and colleagues have shown that 
sodium nitroprusside (an NO donor) reduced the number of gap‐junction‐coupled neurons. 
Nonetheless, NO can affect electrical coupling, synchronization of metabolic states and coor‐
dination of transcriptional activity between connected neurons [40].
6.1.6. Neurotransmitter release and plasticity
Release of several neurotransmitters comprising acetyl choline, catecholamines, glutamate 
and gamma‐Aminobutyric acid (GABA) are regulated by endogenous NO [40]. Furthermore, 
NO involves in balancing between GABAergic and glutamatergic synaptic transmission in 
early post‐natal development. Disruption of this balance precipitates pathological disorders 
such as epilepsy, autism and schizophrenia [42, 43]. Moreover, NO is involved in fine‐tuning 
synchronous network activity in the developing hippocampus [40].
NO plays an important role in memory formation in hippocampus [44] and NOS inhibition 
impedes learning and/or memory [45] while some studies failed to find any effect on learning 
and/or memory [10]. In mature hippocampus, NO regulates LTP at the Schaffer collateral/CA1 
synapses and acts as a retrograde messenger. This occurs via the activation of post‐synaptic 
NMDA receptors, synthesis of NO by NOS expressed in pyramidal cells and then retrograde 
activation of guanylate cyclase located in axon terminals. In contrast, in the cerebellum NO serves 
as an anterograde messenger that is produced in parallel fibre terminals or cerebellar interneu‐
rons and then diffuses to the post‐synaptic Purkinje cell to induce long term depression (LTD) 
through a cGMP‐dependent mechanism [40]. Additionally, NO involves in experience‐depen‐
dent plasticity in the barrel cortex by reduction of bicuculine‐induced activation of Erk and incre‐
ment of c‐Fos, Egr‐1 and Arc.
In water maze, 8‐arm radial maze, passive‐avoidance and elevated plus‐maze, 7‐NI, at a dose 
inhibiting nNOS but not affecting blood pressure, induced amnesic effects. Before training 
in avoidance conditioning in goldfish anterograde amnesia was produced. However, imme‐
diately after training retrograde amnesia was formed. Moreover, genetic inhibition of nNOS 
indicated spatial performance impairment in the Morris water maze [46]. The hippocampus of 
nNOS knockout mice showed an abnormal expression of a synaptosomal‐associated protein 
of the exocytotic machinery, glycolytic enzymes, T‐complex protein 1, the signalling structure 
guanine nucleotide‐binding protein G and heterogeneous nuclear ribonucleoprotein H of the 
splicing machinery. Therefore, in nNOS knockout mice spatial memory in the Morris water 
maze may impair by specific hippocampal protein derangements [10].
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6.1.7. Gastrointestinal tract
The most obvious phenotype of nNOS knockout mice is stomach enlargement, several times 
the normal size, proving a role for nNOS in smooth muscle relaxation of the pyloric sphinc‐
ter. Ablation of exon 6 in another nNOS knockout mice results in severe pyloric stenosis and 
reproductive endocrine abnormalities.
Citrulline measurements showed that nNOS activity in exon 2‐deficient mice is 0.5% of that in 
wild‐type, compared to 3% in exon 6‐deficient mice [47].
6.2. Pathophysiological functions of nNOS
Abnormal NO signalling involved in some neurodegenerative pathologies that include exci‐
totoxicity results in stroke, Parkinson’s and Alzheimer’s diseases and multiple scleroses. NO 
can involve in excitotoxicity, probably by peroxynitrite activation of poly‐ADP‐ribose poly‐
merase (PARP) and/or mitochondrial permeability transition. High levels of NO can also pro‐
duce energy reduction, caused by mitochondrial respiration inhibition and glycolysis. Some 
disorders of smooth muscle tone in the gastrointestinal tract (e.g. gastro‐oesophageal reflux 
disease) may also drive from an excessive NO production by nNOS in peripheral nitrergic 
nerves [4].
An important mode of inactivation of NO is its reaction with superoxide anion (O2‐) to form the potent oxidant peroxynitrite (ONOO‐). This can make oxidative damage, nitration and 
S‐nitrosylation of biomolecules including proteins, lipids and DNA [48]. Nitrosative stress 
by ONOO‐ has been involved in DNA single‐strand breakage, followed by poly‐ADP‐ribose 
polymerase (PARP) activation [49].
6.2.1. Role of nNOS in neurodegeneration
Previous studies have shown that NO implicate in the pathogenesis of some neuroinflam‐
matory/degenerative diseases. The constitutive NOS make the cuprizone‐induced model 
of demyelination/remyelination [50]. Previous results demonstrate that demyelination was 
mainly prevented in mice lacking nNOS. In eNOS‐/‐ mice, demyelination increased to the 
same level as in wild type, but they showed a slight delay in spontaneous remyelination 
[50].
6.2.1.1. Role of nNOS in the pathophysiology of Parkinson's disease
A progressive loss of dopaminergic input from the substantia nigra pars compacta leads to 
overactivity in Parkinson's disease (PD) which creates extrapyramidal motor dysfunction, 
including bradykinesia, rigidity and tremor. 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine 
(MPTP) yield Parkinson‐like symptoms and has been used to assess the mechanism of PD 
pathogenesis.
Recent studies indicate that resistance to MPTP neurotoxicity in the nNOS knockout mice are 
more than wild‐type ones. This was established by 7‐NI that can protect against this neuro‐
toxicity in experimental animals. Furthermore, a great expression of nNOS was reported in 
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basal ganglia and the respiratory burst of circulating neutrophils of PD patients. However, 
NO production and protein tyrosine nitration were considerably increased [10].
L‐DOPA is the most used drug in Parkinson's disease treatment. Nitric oxide is a satisfying 
goal for the decrease of L‐DOPA‐induced dyskinesia in PD [51]. Thus, nNOS in the pathogen‐
esis of Parkinson's disease is important.
6.2.1.2. Role of nNOS in the pathophysiology of Alzheimer's disease
Disruption of neuronal nitric oxide synthase dimerization contributes to the development of 
Alzheimer's disease (AD). nNOS‐Ser293, a potential site of cyclin‐dependent kinase‐5 phos‐
phorylation, may be participated in the nNOS dimerization reduction and, hence, the devel‐
opment of AD [52].
Extracellular accumulation of amyloid β‐peptide (Aβ) causing the neuritic plaques and intra‐
cellular neurofibrillary tangles is due to the tau protein hyperphosphorylation considered to 
be an important feature of AD. Chronic infusion of Aβ1‐40 results in ONOO‐formation and 
subsequent tyrosine nitration of proteins. Nitrotyrosine found in AD was highly co‐localized 
with nNOS in cortical pyramidal cells. Moreover, all three isoforms of NOS are raised up in 
AD; therefore, NOS inhibitors could be useful for AD treatment [10].
6.2.1.3. Role of nNOS in the pathophysiology of multiple sclerosis
Multiple sclerosis (MS) is characterized by demyelination associated with an infiltration of 
mononuclear white blood cells within the CNS. The demyelination leads to diminishing con‐
duction of the action potential in neurons.
nNOS can be induced in nerve injury. It has been revealed that nitric oxide deriving from nNOS 
may be toxic to oligodendrocytes and induce axonal degeneration. Additionally, it is shown 
that nitrate as NO degradation product is increased in cerebrospinal fluid of MS patients. 
Also, the oxidised agent, peroxynitrite is found within active MS lesions. Additionally, NO 
scavengers have been revealed to reduce the severity of an MS‐like disease model [53].
6.2.2. Role of nNOS in the neurodevelopment
Previous studies indicated that nitric oxide derived from nNOS have been associated in social 
interaction. They have shown that nNOS deletion decreased anxiety‐like behaviour, aug‐
mented general locomotor activity, reduced spatial learning and memory, and diminished 
preference for social novelty which are characteristics of autism spectrum disorder [54].
Attention deficit/hyperactivity disorder (ADHD) is a psychiatric disorder with inattention, 
hyperactivity and impulsivity as main signs, and is frequently associated with learning disabil‐
ity, substance abuse, epilepsy and other psychiatric disorders such as anxiety and disruption 
of circadian rhythm [55]. In other study, they reported that NOS1 Ex1f‐VNTR is involved in 
impulsive and empathic personality traits and associated with self‐rated impulsiveness and ven‐
turesomeness [56].
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NOS1 KO exhibited higher locomotor activity than wild‐type in a novel environment, as mea‐
sured by open‐field test. NOS1 KO mimics certain ADHD‐like behaviours and could poten‐
tially serve as a novel rodent model for ADHD.
Recent results propose changes in NO‐signalling pathways may be associated with ADHD in 
humans. Neuronal nitric oxide synthase (NOS1) is a main enzyme responsible for the neu‐
ronal creation of NO. Previous studies show that 28% of adult ADHD patients were found 
to be homozygous for a risk allele in the NOS1 promoter region (termed ex1f‐VNTR) that 
diminishes NOS1 expression. This allele is apparently associated with developed prefrontal 
cortex and ventral striatal roles, which are involved in impulsive and aggressive behaviours 
associated with ADHD. Moreover, past findings showed that NOS1 knockout mice (NOS1 
KO) could be a candidate model for ADHD. Behaviourally, NOS1 KO is apparently hyperac‐
tive and exhibits abnormal social, aggressive and impulsive behaviours as well as deficits in 
learning and memory [55].
6.2.3. Role of nNOS in excitotoxicity
Nitric oxide that occurs naturally in the brain without causing overt toxicity, implicated in cell 
death. One account is that ischaemia creates overproduction of NO, allowing it to react with 
superoxide to form the potent oxidant peroxynitrite [6].
Brain ischaemia is a great pre‐synaptic glutamate release or post‐synaptic stimulation of 
its membrane receptors, reproduce neuronal damage or death. Glutamate by binding to 
four major types of receptors, metabotropic receptors, NMDA receptors, alpha‐amino‐3‐
hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptors, and kainate receptors do its 
action post‐synaptically. Following focal ischaemia, NMDA receptor activation causes more 
glutamate excitotoxicity and neuronal injury than other receptors owning to their high cal‐
cium permeability. Great stimulation of NMDAR results in Ca2+ overload in the cell, and 
therefore triggering the Ca2+‐sensitive enzymes. nNOS, as a Ca2+‐sensitive enzyme, indicates 
a principal role in excitotoxicity. In primary cortical neuronal cultures of nNOS‐/‐ mice, these 
neurons would be resistant to NMDA neurotoxicity and to oxygen‐glucose deprivation com‐
pared with wild‐type cultures. These in vitro studies indicate that nNOS‐derived NO is the 
principal source of neurotoxicity in neurons [10]. nNOS‐/‐ mice have a reduced infarct size, 
under focal ischaemia. nNOS knockout mice are resistant to focal and global cerebral isch‐
aemia, consistent with a role for nNOS‐derived NO in cellular injury following ischaemia.
In addition, 7‐nitroindazole and ARL 17477, as selective nNOS inhibitors, can also decrease 
the infarct size focal ischaemia. Recent studies demonstrate that nNOS expression and enzy‐
matic activity in the hippocampus of mice was decreased under focal cerebral ischaemia. 
The nNOS reduction following ischaemia stimulated cell proliferation in the DG. Therefore, 
nNOS inhibition can improve ischemic injury [10].
Even though NMDA activates NOS, the NOS‐containing neurons resist toxic effects of NMDA 
and form NO that is released to kill adjacent non‐NOS neurons. The unique resistance of NOS 
neurons to NMDA toxicity seems to be associated with their very high content of manganese 
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superoxide dismutase, which blocks interactions of NO with superoxide to form the per‐
oxynitrite [10].
Since NO measuring and localizing is difficult, citrulline as a marker of NO synthase activ‐
ity localized completely to nNOS‐containing neurons and is eliminated following NOS 
inhibitors treatment. Additionally, no other enzyme capable of synthesizing citrulline has 
been found in the brain. Thus, citrulline staining supplies a useful approach to evaluate NO 
turnover [6].
Ischaemia triggers a pronounced enhancement in citrulline immunoreactivity but more so in 
a large population of the neuronal isoform of NO synthase (nNOS) in the peri‐infarct than the 
infarcted tissue. In contrast, 3‐nitrotyrosine (a marker for peroxynitrite formation) is confined 
to the infarcted tissue and is not present in the peri‐infarct tissue.
6.2.4. Mood disorders
NO may play an important role in mediating the effect social interactions have on anxiety. 
Inhibition of nNOS diminishes anxiety‐like responses to pair housing [57]. Also, anxiety‐like 
behaviours in aged mice are recovered by modifying nNOS expression levels in the hippo‐
campus or cerebellum [58].
Major depressive disorder is a mental disorder characterized by at least two weeks of low 
mood that is present across most situations. Paroxetine, a typical anti‐depressant inhibited 
NOS in humans and animals. Moreover, imipramine (IMI, anti‐depressant) significantly 
diminished NOS activity. IMI withdrawal significantly amplified NOS activity. Furthermore, 
plasma nitrate concentrations (indicator of NO production) were highly greater in depressed 
patients. This finding showed likely participation of NO in depression, in line with the 
observation with those 7‐NI made anti‐depressant–like effects in the Forced Swimming Test. 
Interestingly, immobilization‐produced stress elevated nNOS mRNA and protein expression 
in hypothalamic‐pituitary‐adrenal axis in rats. Meanwhile, a recent research showed that 
chronic mild stress (CMS) augmented nNOS expression in the hippocampus. nNOS inhibi‐
tion prevented CMS‐produced depression. In addition, mice with targeted deletion of the 
genes encoding nNOS were resistant to the CMS‐induced  depression [10].
6.2.5. Pain modulation
It is revealed that central anti‐nociceptive effect of tapentadolis augmented by 7NI. Neuronal 
NOS impact on the anti‐nociceptive action of tapentadol at the spinal and supraspinal level [59].
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